PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Osumili, B.* ; Sapin, H.* ; Yang, Z.* ; Ranta, K.* ; Paik, J.S.* ; Blüher, M.

Efficacy and safety of tirzepatide compared with GLP-1 RAs in patients with type 2 diabetes treated with basal insulin: A network meta-analysis.

Diabetes Ther. 16, 1279-1311 (2025)
Verlagsversion DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
INTRODUCTION: The relative efficacy and safety of tirzepatide was compared with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes mellitus (T2DM) treated with basal insulin using a network meta-analysis (NMA). METHODS: A systematic literature review was performed to identify randomized controlled trials of GLP-1 RAs in patients with T2DM treated with insulin and an antihyperglycaemic drug. For the NMA, studies included trials with 100% of patients treated with basal insulin background therapy with a titration scheme comparable to the SURPASS-5 trial. The following data were extracted for efficacy and safety assessment at the primary endpoint of each study: changes from baseline in glycated haemoglobin (HbA1c) and body weight and the incidence of nausea, vomiting or diarrhoea, hypoglycaemia, and patients discontinuing treatment because of adverse events. In this study, a comparative analysis of tirzepatide was performed with the GLP-1 RAs dulaglutide, exenatide, and lixisenatide in addition to placebo. RESULTS: A total of six studies were included across the analyses. Tirzepatide 5, 10, and 15 mg showed statistically significant, greater reductions in HbA1c and body weight at the primary endpoint versus all GLP-1 RA comparators and placebo. Tirzepatide 5, 10, and 15 mg showed a statistically significant, higher likelihood of experiencing nausea compared with those who received placebo or exenatide 2 mg; no statistically significant differences were observed when compared with all other GLP-1 RA comparators. No statistically significant differences were observed in the proportions of patients who discontinued treatment because of adverse events when tirzepatide 5, 10, and 15 mg were compared with GLP-1 RA comparators, apart from tirzepatide 10 and 15 mg versus placebo. CONCLUSION: Tirzepatide demonstrated statistically significantly greater reductions in HbA1c and body weight when compared with selected GLP-1 RAs and placebo in patients with T2DM treated with basal insulin. Overall, the safety profile of tirzepatide was similar to that of GLP-1RAs.
Impact Factor
Scopus SNIP
Altmetric
2.600
0.000
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Basal Insulin ; Glp-1 Receptor Agonists ; Glycaemic Control ; Network Meta-analysis ; Tirzepatide ; Type 2 Diabetes Mellitus; Peptide-1 Receptor Agonist; Once-weekly Semaglutide; Placebo-controlled Trial; Beta-cell Function; Randomized Clinical-trial; Achieve Glycemic Control; Oral Antidiabetic Drugs; Fixed-ratio Combination; Twice-daily Exenatide; To-target Trial
Sprache englisch
Veröffentlichungsjahr 2025
HGF-Berichtsjahr 2025
ISSN (print) / ISBN 1869-6961
e-ISSN 1869-6953
Zeitschrift Diabetes Therapy
Quellenangaben Band: 16, Heft: 6, Seiten: 1279-1311 Artikelnummer: , Supplement: ,
Verlag Springer
Verlagsort New York, NY [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Helmholtz Institute for Metabolism, Obesity and Vascular Research (HI-MAG)
POF Topic(s) 30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
PSP-Element(e) G-506501-001
Förderungen John Downey of Eli Lilly and Company
Eli Lilly and Company
DOI 10.1007/s13300-025-01728-5
WOS ID 001464541100001
Scopus ID 105002348998
PubMed ID 40214900
Erfassungsdatum 2025-05-10
[➜Korrektur melden]